What Brands Are Owned By Johnson and Johnson?

What brands are owned by Johnson and Johnson? This question reveals a vast array of companies and products across various sectors. Johnson & Johnson is a global healthcare leader with a diverse portfolio. Their reach extends from trusted consumer brands to cutting-edge medical technologies. Understanding their ownership provides insight into the company’s influence on daily life and healthcare.

Key Takeaways

• Johnson & Johnson owns a diverse portfolio of major healthcare brands, including Janssen Pharmaceuticals, DePuy Synthes, Ethicon, Acclarent, LifeScan, Mentor Worldwide, Ci:z Holdings, V-Wave, Shockwave Medical, and Biosense Webster.
• Its brands span pharmaceuticals, medical devices, and specialized health technologies, making it a leader in global healthcare innovation.
• These brands contribute to significant financial strength, with $90.6 billion in revenue and a market capitalization of $426.6 billion as of September 2025.

Johnson and Johnson Company Profile

Johnson & Johnson is a global healthcare giant that operates across three major sectors: pharmaceuticals, medical devices, and consumer health products. The company is renowned for its commitment to improving human health and well-being through innovation and high-quality products. Its brands, such as Band-Aid, Tylenol, and Neutrogena, have become household names worldwide.

Johnson & Johnson’s influence spans over 60 countries, and it employs more than 130,000 people globally. Its diverse portfolio allows it to cater to various healthcare needs, from everyday wellness to specialized medical treatments.

Founders

Johnson & Johnson was founded by three brothers: Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson.

The brothers shared a vision of creating sterile surgical products to improve patient outcomes. Robert Wood Johnson played a particularly pivotal role in shaping the company’s early strategy and focus on hygiene and medical innovation.

The founders’ emphasis on quality, safety, and public health laid the groundwork for Johnson & Johnson’s long-term growth and global reputation.

Major Milestones

• 1886: Johnson & Johnson is founded in New Brunswick, New Jersey, focusing on sterile surgical supplies.
• 1888: Introduces the first ready-to-use surgical dressings, improving surgical safety.
• 1890: Launches Johnson’s Baby Powder, marking entry into consumer health products.
• 1911: Expands internationally with the first foreign subsidiary in Canada.
• 1921: Introduces Band-Aid adhesive bandages, a revolutionary consumer product.
• 1953: Establishment of Janssen Pharmaceuticals, which becomes a key player in prescription medicine.
• 1961: Janssen Pharmaceuticals is fully integrated into Johnson & Johnson.
• 1970: Expands medical device division, including surgical instruments and orthopedic products.
• 1980: Acquires various healthcare companies to strengthen the pharmaceutical and device portfolio.
• 1994: Acquisition of Neutrogena, marking a major move into consumer skincare.
• 1998: Acquisition of DePuy, enhancing Johnson & Johnson’s orthopedics division.
• 2003: Introduces the first biologic therapies through Janssen for autoimmune diseases.
• 2009: Acquisition of Mentor Worldwide, strengthening its presence in aesthetic medicine.
• 2010: Acclarent, a specialized ENT medical device company, becomes part of Johnson & Johnson.
• 2016: Launches new initiatives in digital health and robotics-assisted surgery.
• 2019: Acquires Ci:z Holdings, expanding its presence in the Asian skincare market.
• 2023: Spins off consumer health division into Kenvue, focusing Johnson & Johnson on pharmaceuticals and medical devices.
• 2024: Johnson & Johnson acquires Shockwave Medical for $12.5 billion, enhancing its heart device business with innovative technologies for treating calcified arterial plaque.
• 2025: Johnson & Johnson is named to Fortune’s 2025 America’s Most Innovative Companies list, recognizing its commitment to developing solutions that address global health challenges.

List of Brands Owned by Johnson and Johnson

Johnson & Johnson, a global leader in healthcare, operates an extensive portfolio of brands and subsidiaries across pharmaceuticals, medical devices, and consumer health products.

Following the spin-off of its consumer health division into Kenvue in 2023, Johnson & Johnson has honed its focus on high-growth areas within the healthcare sector.

Below is a detailed overview of the key entities under Johnson & Johnson’s ownership as of 2025:

Janssen Pharmaceuticals

Janssen Pharmaceuticals is a cornerstone of Johnson & Johnson’s pharmaceutical division, specializing in treatments for various therapeutic areas, including oncology, immunology, neuroscience, and infectious diseases. The division is recognized for its innovative drug development and commitment to addressing unmet medical needs.

Actelion Pharmaceuticals

Actelion Pharmaceuticals, acquired by Johnson & Johnson in 2017, is a biopharmaceutical company specializing in treatments for pulmonary arterial hypertension and other serious diseases. The division operates within Johnson & Johnson’s pharmaceutical segment, focusing on high-impact therapies.

Momenta Pharmaceuticals

Momenta Pharmaceuticals, acquired by Johnson & Johnson in 2020, is a biotechnology company focusing on rare diseases and autoimmune disorders. The division contributes to Johnson & Johnson’s commitment to addressing complex medical challenges.

Intra-Cellular Therapies

Intra-Cellular Therapies, acquired by Johnson & Johnson in 2025, specializes in medications for behavioral disorders, including schizophrenia, depression, and bipolar disorder. The division operates as a business unit within Johnson & Johnson Innovative Medicine, contributing to the company’s leadership in neuroscience.

Biosense Webster

Biosense Webster, a subsidiary of Johnson & Johnson, specializes in electrophysiology and cardiac mapping technologies. The division provides solutions for diagnosing and treating heart rhythm disorders, enhancing patient outcomes in cardiology.

Cerenovus

Cerenovus, part of Johnson & Johnson MedTech, focuses on neurovascular solutions, offering products for the treatment of stroke and other cerebrovascular conditions. The division is dedicated to advancing care in neurointerventional procedures.

Johnson & Johnson Vision

Johnson & Johnson Vision provides a range of eye care products, including contact lenses and surgical solutions for vision correction. The division aims to improve eye health and quality of life through innovative vision care products.

Johnson & Johnson Health Technologies

Johnson & Johnson Health Technologies focuses on developing digital health solutions and technologies to support patient care. The division leverages data analytics and technology to enhance healthcare delivery and patient engagement.

Johnson & Johnson Services

Johnson & Johnson Services offers a variety of services to support the company’s operations, including IT, supply chain, and regulatory affairs. The division plays a crucial role in ensuring the efficiency and compliance of Johnson & Johnson’s global operations.

Johnson & Johnson Enterprise Innovation

Johnson & Johnson Enterprise Innovation is dedicated to fostering innovation across the company’s businesses. The division collaborates with internal and external partners to develop new technologies and solutions that drive growth and improve healthcare outcomes.

Johnson & Johnson Health Care Systems

Johnson & Johnson Health Care Systems focuses on providing healthcare solutions and services to institutions and professionals. The division aims to enhance patient care and healthcare delivery through strategic partnerships and support services.

Johnson & Johnson Innovation

Johnson & Johnson Innovation is a subsidiary of Johnson & Johnson that focuses on early-stage, life science, and technology innovations to advance the company’s research and development pipeline. It provides startups with sourcing, infrastructure, and capital equipment at JLABS, financing & venture capital at JJDC, Inc., and collaborations leading to the potential development of medical device technologies, pharmaceuticals, and therapeutics.

Johnson & Johnson MedTech

Johnson & Johnson MedTech is a division that encompasses various medical technology companies, including:

• DePuy Synthes: A leading provider of orthopedic and neuro products, offering solutions for joint reconstruction, spine surgery, trauma care, and sports medicine.
• Ethicon: Focuses on surgical products, providing a wide array of solutions such as sutures, staplers, and wound care products.
• Acclarent: Specializes in ear, nose, and throat (ENT) medical devices, offering minimally invasive solutions for sinus and airway conditions.
• LifeScan: Develops and markets blood glucose monitoring systems, including the OneTouch brand, widely used by individuals with diabetes to manage their condition effectively.
• Mentor Worldwide: A global leader in aesthetic medicine, specializing in breast aesthetics and body contouring products.
• Ci:z Holdings: A Japan-based company that develops and markets cosmetics products under brands such as DR. CI:LABO, LABO LABO, and GENOMER.
• V-Wave: Acquired by Johnson & Johnson in 2024, V-Wave is a company focused on developing innovative treatment options for patients with heart failure.
• Shockwave Medical: Acquired by Johnson & Johnson in 2024, Shockwave Medical develops devices that use shockwaves to break down calcified plaque in heart vessels.
• Abiomed: Acquired by Johnson & Johnson in 2022, Abiomed is a cardiovascular medical technology company known for its heart pump devices.
• Biosense Webster: Specializes in electrophysiology and cardiac mapping technologies, providing solutions for diagnosing and treating heart rhythm disorders.
• Cerenovus: Focuses on neurovascular solutions, offering products for the treatment of stroke and other cerebrovascular conditions.
• Johnson & Johnson Vision: Provides a range of eye care products, including contact lenses and surgical solutions for vision correction.
• Johnson & Johnson Health Technologies: Focuses on developing digital health solutions and technologies to support patient care.
• Johnson & Johnson Services: Offers a variety of services to support the company’s operations, including IT, supply chain, and regulatory affairs.
• Johnson & Johnson Enterprise Innovation: Dedicated to fostering innovation across the company’s businesses, collaborating with internal and external partners to develop new technologies and solutions.
• Johnson & Johnson Health Care Systems: Focuses on providing healthcare solutions and services to institutions and professionals.

Who Owns Johnson and Johnson: Top Shareholders

Johnson & Johnson is a publicly traded company, meaning it does not have a single owner. Its shares are predominantly held by institutional investors, who collectively control about 65% of the company, while the remaining 35% are held by individual and retail investors. These shareholders influence the company’s governance, strategic decisions, and long-term growth.

Below is a list of the largest, major shareholders of Johnson & Johnson as of September 2025:

The Vanguard Group

The Vanguard Group is Johnson & Johnson’s largest shareholder, holding 233.96 million shares, which accounts for 9.72% of the company. Vanguard’s stake allows it to participate actively in corporate governance and voting on key issues. Its investment reflects confidence in J&J’s diversified healthcare portfolio and consistent financial performance.

BlackRock, Inc.

BlackRock, Inc. owns 199.37 million shares, equivalent to 8.29% of Johnson & Johnson’s outstanding shares. As a major institutional investor, BlackRock exercises influence over board decisions and long-term strategic planning, supporting initiatives that drive sustainable growth and innovation.

State Street Corporation

State Street Corporation holds 132.80 million shares, representing 5.50% of the company. Its investment is focused on long-term value creation, risk management, and supporting initiatives that enhance Johnson & Johnson’s market leadership and operational efficiency.

Geode Capital Management

Geode Capital Management owns 60.60 million shares, or 2.52% of the company. Geode’s stake allows it to engage in shareholder activities and advocate for strategies that promote stable growth and strong returns on investment.

Morgan Stanley

Morgan Stanley holds 43.70 million shares, accounting for 1.82% of Johnson & Johnson. The firm’s investment emphasizes long-term performance and aligns with its broader portfolio of healthcare sector holdings.

JPMorgan Chase & Co.

JPMorgan Chase & Co. owns 36.70 million shares, which is about 1.52% of the company. Its involvement ensures that shareholder interests are represented in corporate governance while supporting sustainable financial strategies.

State Farm Mutual Automobile Insurance Company

State Farm holds 31.90 million shares, representing 1.32% of Johnson & Johnson. As a long-term investor, State Farm contributes to the company’s stability and supports initiatives that strengthen operational efficiency and innovation.

Norges Bank Investment Management

Norges Bank holds 31.90 million shares, or 1.33% of the company. Its investment strategy focuses on stable returns and long-term growth, ensuring continued support for Johnson & Johnson’s core businesses.

Northern Trust Corporation

Northern Trust Corporation owns 30.70 million shares, equaling 1.28% of Johnson & Johnson. Northern Trust’s stake allows it to participate in governance and contribute to strategic decision-making processes that reinforce the company’s market position.

Wellington Management Group

Wellington Management Group holds 24.20 million shares, or 1.01% of the company. Its investment emphasizes growth and innovation in healthcare, helping Johnson & Johnson maintain leadership in pharmaceuticals, medical devices, and other key sectors.

Who is the CEO of Johnson & Johnson?

As of September 2025, the Chief Executive Officer (CEO) of Johnson & Johnson is Joaquin Duato. He has been serving as CEO since January 2022 and assumed the role of Chairman in January 2023. Duato is the eighth CEO in the company’s history since it became publicly traded in 1944.

Early Life and Education

Joaquin Duato was born in April 1962 in Valencia, Spain. His upbringing was influenced by a family deeply rooted in healthcare; his mother was a nurse, his grandfather a pediatrician, and his grandmother a pharmacist. Duato is fluent in Spanish, English, and Italian.

He holds a Master of Business Administration (MBA) from ESADE Business School in Barcelona, Spain, and a Master of International Management from the Thunderbird School of Global Management in Phoenix, Arizona. Duato holds dual citizenship in Spain and the United States.

Career at Johnson & Johnson

Duato began his career with Johnson & Johnson in 1989, joining Janssen Pharmaceuticals in Spain.

In 2002, he moved to the United States and was appointed Executive Vice President, Worldwide Chairman, Pharmaceuticals in 2011. His strategic leadership played a pivotal role in turning around Johnson & Johnson’s pharmaceutical business in the early 2000s.

In 2018, Duato was promoted to Vice Chairman of the Executive Committee, overseeing the pharmaceutical and consumer health businesses, as well as technology and global supply chain operations. He also served as interim Chief Information Officer during this period.

Leadership as CEO

Duato’s appointment as CEO in January 2022 marked a significant shift for Johnson & Johnson. Under his leadership, the company has focused on developing innovative medicines and medical technology solutions.

Duato has emphasized the importance of accelerating healthcare innovation through data science and the latest technology, aiming to create breakthroughs in care, from cell therapy to robotic-assisted surgery.

Strategic Vision and Achievements

One of Duato’s key initiatives was overseeing the separation of Johnson & Johnson’s consumer health segment, which became the independent publicly traded company Kenvue in 2023.

This strategic move allowed Johnson & Johnson to concentrate on high-growth areas within the healthcare sector, particularly pharmaceuticals and medical technologies.

Under Duato’s leadership, Johnson & Johnson has invested over $60 billion in research and development, as well as acquisitions, including the purchase of Intra-Cellular Therapies. This investment underscores the company’s commitment to addressing complex medical challenges and advancing healthcare standards.

Personal Leadership Style

Duato is known for his servant leadership approach, emphasizing the importance of continuous learning and fostering a culture of innovation within the company. He has advocated for improving drug affordability by addressing intermediary costs and has highlighted the necessity of collaboration with governmental and healthcare entities to enhance patient access to treatments.

Compensation and Recognition

In 2023, Duato was the highest-paid CEO among major U.S. pharmaceutical companies, earning $28.4 million, a 117% increase over his 2022 compensation. This reflects the company’s confidence in his leadership and the positive direction under his stewardship.

Outlook for the Future

Looking ahead, Duato remains focused on advancing healthcare innovation, particularly in the areas of neuroscience, cardiovascular health, and rare diseases. His leadership continues to steer Johnson & Johnson toward its mission of tackling the toughest health challenges by developing innovative medicines and medical technology solutions.

Johnson & Johnson Annual Revenue and Net Worth

As of September 2025, Johnson & Johnson continues to be a global leader in healthcare, reporting a robust revenue of approximately $90.6 billion and a market capitalization of around $426.6 billion. The company’s strong financial performance reflects its focus on innovative pharmaceuticals and advanced medical technologies, positioning it as one of the most valuable and influential healthcare companies in the world.

Annual Revenue

As of 2025, Johnson & Johnson has demonstrated strong financial performance, reflecting its focus on pharmaceuticals and medical technologies. The company reported a total revenue of approximately $90.6 billion for the trailing twelve months ending June 30, 2025.

The pharmaceutical segment accounted for around 60% of total revenue, driven by innovative medicines across oncology, immunology, neuroscience, and infectious diseases.

The MedTech division contributed roughly 40% of revenue, supported by surgical, orthopedic, cardiovascular, and vision care products. Compared to the previous year, Johnson & Johnson achieved a year-over-year revenue increase of about 4.7%, with Q1 2025 sales at $21.9 billion, marking a 2.4% increase from the prior year, and Q2 2025 sales of $23.7 billion, a 5.8% rise.

Net Income

Johnson & Johnson’s net income for 2025 reached $26.65 billion, reflecting a significant increase of 89.5% compared to $14.07 billion in 2024.

Earnings per share (EPS) also showed strong performance, with Q1 2025 EPS at $4.54, surpassing analyst expectations, and Q2 2025 EPS reported at $2.29, or $2.77 on an adjusted basis.

This growth in net income highlights the company’s successful execution of its strategy, including investment in high-growth therapeutic areas and operational efficiency improvements.

Net Worth

As of September 2025, Johnson & Johnson’s market capitalization stands at approximately $426.6 billion, with its stock trading around $177.73 per share. This represents a year-over-year increase of 6.16% in market value.

The company’s strong market position reflects investor confidence in its diversified portfolio and strategic focus on innovation in pharmaceuticals and MedTech.

Johnson & Johnson has raised its full-year 2025 revenue guidance to between $91.0 billion and $91.8 billion, up from the previous estimate of $90.0 billion.

Adjusted EPS guidance remains in the range of $10.50 to $10.70, indicating steady profitability.

The company has continued to make significant investments, including the $14.6 billion acquisition of Intra-Cellular Therapies, enhancing its portfolio in neuroscience. In addition, Johnson & Johnson plans to invest over $55 billion in the U.S. over the next four years to strengthen domestic manufacturing capabilities and support future growth.

Final Words

Johnson & Johnson’s extensive portfolio encompasses a wide range of brands and subsidiaries. From pharmaceuticals to consumer health products, the company has a significant impact on global healthcare. Understanding the brands owned by Johnson & Johnson provides insight into its operations and influence in the industry.

FAQs

What are some of the most popular brands owned by Johnson & Johnson?

Some of the most popular brands owned by Johnson & Johnson include Band-Aid, Tylenol, Neutrogena, and Listerine. These brands are widely recognized and trusted by consumers worldwide.

How many companies are under Johnson & Johnson?

Johnson & Johnson owns and operates over 20 major subsidiaries and brands globally, spanning pharmaceuticals, medical devices, and specialized healthcare technologies. This includes key companies like Janssen Pharmaceuticals, DePuy Synthes, Ethicon, Acclarent, LifeScan, Mentor Worldwide, Ci:z Holdings, V-Wave, Shockwave Medical, and Biosense Webster.

What is the main product of Johnson & Johnson?

Johnson & Johnson does not rely on a single product; its main focus is innovative pharmaceuticals and medical devices. Key product lines include prescription medicines from Janssen Pharmaceuticals, surgical instruments from Ethicon, orthopedic solutions from DePuy Synthes, and diabetes care devices from LifeScan.

What are the major Johnson & Johnson products?

Major products under Johnson & Johnson include Band-Aid, OneTouch glucose monitors, Ethicon surgical devices, DePuy orthopedic implants, Acclarent ENT devices, Mentor aesthetic products, Ci:z Holdings skincare products, Shockwave Medical cardiovascular devices, and V-Wave heart failure solutions. These products span both therapeutic and medical technology areas.

What is the Johnson & Johnson brands list?

Johnson & Johnson’s brands and subsidiaries include Janssen Pharmaceuticals, DePuy Synthes, Ethicon, Acclarent, LifeScan, Mentor Worldwide, Ci:z Holdings, V-Wave, Shockwave Medical, Biosense Webster, Cerenovus, and Johnson & Johnson Vision, among others focused on healthcare, MedTech, and life sciences innovation.

What does J&J own?

J&J owns a broad portfolio of pharmaceutical companies, medical device firms, digital health technology divisions, and specialized healthcare brands. Key holdings include Janssen Pharmaceuticals, DePuy Synthes, Ethicon, Mentor Worldwide, Ci:z Holdings, LifeScan, Acclarent, Shockwave Medical, V-Wave, and Biosense Webster.

Is Pfizer owned by Johnson & Johnson?

No, Pfizer is an independent pharmaceutical company and is not owned by Johnson & Johnson.

Who is Aveeno owned by?

Aveeno is owned by Kenvue, the consumer health company spun off from Johnson & Johnson in 2023. Johnson & Johnson itself no longer owns Aveeno.

Is Dove a Johnson and Johnson company?

No, Dove is owned by Unilever, not Johnson & Johnson.

Are Aveeno and Johnson the same?

No, Aveeno is now part of Kenvue, the spun-off consumer health company, and is separate from Johnson & Johnson, which focuses on pharmaceuticals and medical devices.

What country is Aveeno from?

Aveeno was originally developed in the United States and continues to be a U.S.-based skincare brand under Kenvue.